Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar

Stifel Reiterates Buy on Momenta Pharma (MNTA) Following Positive Phase 3 Data

November 29, 2016 10:28 AM EST

Stifel reiterated a Buy rating and $20.00 price target on Momenta Pharmaceuticals (NASDAQ: MNTA) following the company's positive Phase 3 data for Humira.

Analyst Thomas Shrader commented, "Momenta reported positive Phase 3 data in patients with moderate to severe plaque psoriasis for its biosimilar Humira... More